AstraZeneca PLC (AZN)
64.25
+1.05
(+1.66%)
USD |
NASDAQ |
Nov 21, 16:00
64.28
+0.03
(+0.05%)
After-Hours: 18:08
AstraZeneca Revenue (Quarterly): 13.56B for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 13.56B |
| June 30, 2024 | 12.94B |
| March 31, 2024 | 12.68B |
| December 31, 2023 | 12.02B |
| September 30, 2023 | 11.49B |
| June 30, 2023 | 11.42B |
| March 31, 2023 | 10.88B |
| December 31, 2022 | 11.21B |
| September 30, 2022 | 10.98B |
| June 30, 2022 | 10.77B |
| March 31, 2022 | 11.39B |
| December 31, 2021 | 12.01B |
| September 30, 2021 | 9.866B |
| June 30, 2021 | 8.22B |
| March 31, 2021 | 7.32B |
| December 31, 2020 | 7.41B |
| September 30, 2020 | 6.578B |
| June 30, 2020 | 6.275B |
| March 31, 2020 | 6.354B |
| December 31, 2019 | 6.664B |
| September 30, 2019 | 6.406B |
| June 30, 2019 | 5.823B |
| March 31, 2019 | 5.491B |
| December 31, 2018 | 6.417B |
| September 30, 2018 | 5.34B |
| Date | Value |
|---|---|
| June 30, 2018 | 5.155B |
| March 31, 2018 | 5.178B |
| December 31, 2017 | 5.777B |
| September 30, 2017 | 6.232B |
| June 30, 2017 | 5.051B |
| March 31, 2017 | 5.405B |
| December 31, 2016 | 5.585B |
| September 30, 2016 | 5.699B |
| June 30, 2016 | 5.603B |
| March 31, 2016 | 6.115B |
| December 31, 2015 | 6.399B |
| September 30, 2015 | 5.945B |
| June 30, 2015 | 6.307B |
| March 31, 2015 | 6.057B |
| December 31, 2014 | 6.716B |
| September 30, 2014 | 6.609B |
| June 30, 2014 | 6.762B |
| March 31, 2014 | 6.46B |
| December 31, 2013 | 6.939B |
| September 30, 2013 | 6.25B |
| June 30, 2013 | 6.232B |
| March 31, 2013 | 6.385B |
| December 31, 2012 | 7.282B |
| September 30, 2012 | 6.682B |
| June 30, 2012 | 6.66B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
6.275B
Minimum
Jun 2020
13.56B
Maximum
Sep 2024
10.00B
Average
10.93B
Median
Revenue (Quarterly) Benchmarks
| GSK PLC | 10.43B |
| Amgen Inc | 8.503B |
| Johnson & Johnson | 22.47B |
| Sanofi SA | 15.57B |
| Moderna Inc | 1.855B |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 1.429B |
| Total Expenses (Quarterly) | 11.46B |
| EPS Diluted (Quarterly) | 0.455 |
| Enterprise Value | 221.25B |
| Gross Profit Margin (Quarterly) | 77.29% |
| Profit Margin (Quarterly) | 10.53% |
| Earnings Yield | 3.25% |
| Operating Earnings Yield | 5.36% |
| Normalized Earnings Yield | 3.855 |